ethyl (3-[(benzylsulfonyl)amino]-2-oxo-1,2-dihydropyridyl)acetate | 179523-52-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl (3-[(benzylsulfonyl)amino]-2-oxo-1,2-dihydropyridyl)acetate
• 英文别名: ethyl 2-[3-(benzylsulfonylamino)-2-oxopyridin-1-yl]acetate
• CAS: 179523-52-5
• 化学式: C₁₆H₁₈N₂O₅S
• 分子量: 350.395
• InChiKey: OQDAHUSCNAVLEZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  24
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  101
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ethyl (3-[(benzylsulfonyl)amino]-2-oxo-1,2-dihydropyridyl)acetate 在 lithium hydroxide 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-[(2S)-5-[[amino-[(4-methylphenyl)sulfonylamino]methylidene]amino]-1-oxo-1-(1,3-thiazol-2-yl)pentan-2-yl]-2-[3-(benzylsulfonylamino)-2-oxopyridin-1-yl]acetamide
  参考文献：
  名称：

  Design, synthesis, and structure–Activity relationships of unsubstituted piperazinone-Based transition state factor Xa inhibitors

  摘要：

  A series of novel transition state factor Xa inhibitors containing a variety, of lactam ring systems as central templates was synthesized in an expedient manner and allowed for a great deal of structural variability. Among them. the piperazinone-based inhibitors were found to be not only active against factor Xa but also selective over thrombin. Optimization of the P4 moiety yielded several potent compounds with IC50 below 1 nM against factor Xa. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)01037-5
• 作为产物：
  描述：

  乙基(3-硝基-2-氧代-1(2H)-吡啶基)乙酸酯 在 palladium on activated charcoal 氢气 、 三乙胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 ethyl (3-[(benzylsulfonyl)amino]-2-oxo-1,2-dihydropyridyl)acetate
  参考文献：
  名称：

  Design, synthesis, and structure–Activity relationships of unsubstituted piperazinone-Based transition state factor Xa inhibitors

  摘要：

  A series of novel transition state factor Xa inhibitors containing a variety, of lactam ring systems as central templates was synthesized in an expedient manner and allowed for a great deal of structural variability. Among them. the piperazinone-based inhibitors were found to be not only active against factor Xa but also selective over thrombin. Optimization of the P4 moiety yielded several potent compounds with IC50 below 1 nM against factor Xa. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)01037-5

文献信息

• Selective factor Xa inhibitors
  申请人：COR Therapeutics, Inc.

  公开号：US06369080B2

  公开（公告）日：2002-04-09

  Novel compounds of formula I: including its pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating conditions in mammals characterized by undesired thrombosis.

  公式I的新化合物：包括其药用可接受的异构体、盐、水合物、溶剂合物和前药衍生物，具有对哺乳动物凝血因子Xa活性的描述。还描述了含有这种化合物的组合物。这些化合物和组合物在体外或体内用于预防或治疗哺乳动物中由不良血栓形成特征的疾病。
• Aromatic heterocyclic derivatives as enzyme inhibitors
  申请人：Corvas International, Inc.

  公开号：US06342504B1

  公开（公告）日：2002-01-29

  The present invention discloses peptide aldehydes which are potent and specific inhibitors of thrombin, their pharmaceutically acceptable salts, pharmaceutically acceptable compositions thereof, and methods of using them as therapeutic agents for disease states in mammals characterized by abnormal thrombosis.

  本发明公开了肽醛，它们是凝血酶的强效和特异性抑制剂，其药用可接受的盐，药用可接受的组合物以及使用它们作为治疗哺乳动物病态血栓形成的方法。
• Aromatic hetherocyclic derivatives as enzyme inhibitors
  申请人：Corvas International, Inc.

  公开号：US06008351A1

  公开（公告）日：1999-12-28

  The present invention discloses peptide aldehydes which are potent and specific inhibitors of thrombin, their pharmaceutically acceptable salts, pharmaceutically acceptable compositions thereof, and methods of using them as therapeutic agents for disease states in mammals characterized by abnormal thrombosis.

  本发明公开了肽醛，它们是强效且特异的凝血酶抑制剂，其药用盐、药用组合物以及将它们用作治疗哺乳动物中由异常血栓形成特征的疾病状态的方法。
• Design, synthesis, and structure–Activity relationships of unsubstituted piperazinone-Based transition state factor Xa inhibitors
  作者：Wenrong Huang、Mary Ann Naughton、Hua Yang、Ting Su、Suiko Dam、Paul W. Wong、Ann Arfsten、Susan Edwards、Uma Sinha、Stanley Hollenbach、Robert M. Scarborough、Bing-Yan Zhu

  DOI：10.1016/s0960-894x(02)01037-5

  日期：2003.2

  A series of novel transition state factor Xa inhibitors containing a variety, of lactam ring systems as central templates was synthesized in an expedient manner and allowed for a great deal of structural variability. Among them. the piperazinone-based inhibitors were found to be not only active against factor Xa but also selective over thrombin. Optimization of the P4 moiety yielded several potent compounds with IC50 below 1 nM against factor Xa. (C) 2003 Elsevier Science Ltd. All rights reserved.